---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-096346"
form_type: "8-K"
ticker: "HYPD"
cik: "0001682639"
company_name: "HYPERION DEFI, INC."
filed_at: "2023-08-29T23:59:59+00:00"
generated_at: "2026-06-11T02:24:43.983364+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eyenovia raises $12M in registered direct offering of common stock and warrants

## Summary
- Offering 4.2M shares, pre-funded warrants for 2.25M shares, and 4.8M warrants at combined price of $1.86/share.
- Gross proceeds $12M; net estimated at $10.9M after placement agent fees and expenses.
- Proceeds to fund post-ophthalmic surgery product (PDUFA March 2024, $1.3B market), Optejet automation, working capital.
- Prior warrants amended: exercise price cut from $3.54 to $2.23, term extended to March 2029, contingent on closing.
- Expected close August 29, 2023; William Blair sole lead placement agent.

## SEC filing metadata
- accession: 0001104659-23-096346
- form_type: 8-K
- ticker: HYPD
- cik: 0001682639
- company_name: HYPERION DEFI, INC.
- filed_at: 2023-08-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/0001104659-23-096346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/tm2324923d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-096346
- JSON: https://secwatch.observer/filing/0001104659-23-096346.json
- Plain text: https://secwatch.observer/filing/0001104659-23-096346.txt

## Key facts
- Material Agreements
  HYPERION DEFI, INC. amended Warrant Amendment Agreement with the holder of previously issued warrants valued at amended Prior Warrants to reduce exercise price to $2.23 per share and extend term to March 1, 2029 (effective 2023-08-24).
  - Action: amendment
  - Counterparty: the holder of previously issued warrants
  - Value: amended Prior Warrants to reduce exercise price to $2.23 per share and extend term to March 1, 2029
  - Effective: 2023-08-24
  source text: the Company entered into a warrant amendment agreement (the “Amendment”) with the holder (the “Holder”) of previously issued warrants (the “Prior Warrants”) to purchase up to 4,870,130 shares of Common Stock, whereby the Company agreed to amend the Prior Warrants to (i) reduce the exercise price of the Prior Warrants from $3.54 per share of Common Stock to $2.23 per share of Common Stock, (ii) extend the term of the Prior Warrants until March 1, 2029, (iii) include a stockholder approval requirement in connection with a modification of the beneficial ownership limitation contained in the Prior Warrants, and (iv) prohibit exercise of the Prior Warrants for the six-month period following the effective date of the Amendment, in each case, in accordance with the terms of the Amendment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/0001104659-23-096346-index.htm
- Material Agreements
  HYPERION DEFI, INC. entered into Securities Purchase Agreement with a certain institutional and accredited investor valued at aggregate gross proceeds approximately $10.9 million (effective 2023-08-24).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: a certain institutional and accredited investor
  - Value: aggregate gross proceeds approximately $10.9 million
  - Effective: 2023-08-24
  source text: On August 24, 2023, Eyenovia, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional and accredited investor (the “Purchaser”), pursuant to which the Company agreed to sell, in a registered direct offering by the Company directly to the Purchaser (the “Offering”), 4,198,633 shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), pre-funded warrants to purchase up to 2,252,979 shares of Common Stock (the “Pre-Funded Warrants”) and warrants to purchase up to 4,838,709 shares of Common Stock (the “Warrants” and, together with the Shares and the Pre-Funded Warrants, the “Securities”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1682639/000110465923096346/0001104659-23-096346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.